drugset
drugset / Trial / NCT06349408

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06349408 ↗

Phase 1 Recruiting 250 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Timeline

Start
2025-01-10
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI3001 Unknown — Intravenous

Indications

No indication recorded.